Product of the Physician Global Assessment and body surface area: A simple static measure of psoriasis severity in a longitudinal cohort

2013 ◽  
Vol 69 (6) ◽  
pp. 931-937 ◽  
Author(s):  
Jessica A. Walsh ◽  
Molly McFadden ◽  
Jamie Woodcock ◽  
Daniel O. Clegg ◽  
Philip Helliwell ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Global Assessment ◽  
Physician Global Assessment ◽  
Longitudinal Cohort ◽  
Psoriasis Severity

Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting

2017 ◽  
Vol 44 (5) ◽  
pp. 691-692 ◽  
Author(s):  
Joseph F. Merola ◽  
Alice B. Gottlieb
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Surface Area ◽  
Annual Meeting ◽  
Body Surface Area ◽  
Body Surface ◽  
Clinical Setting ◽  
Global Assessment ◽  
Clinical Severity

At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), we presented the case for quantitatively assessing the extent of both psoriasis and psoriatic arthritis in the clinical setting, with a particular focus on the validation and expanded novel use of the PGAxBSA (static physician’s global assessment × body surface area of involvement) in the era of targeted metrics. Herein, we summarize our presentation.

Open-Label, Observational Pilot Study Evaluating Desoximetasone Topical Spray 0.25% Twice Daily in Patients With Psoriasis Being Treated With Biologic Agents

2018 ◽  
Vol 3 (1) ◽  
pp. 10-14
Author(s):  
Jerry Bagel ◽  
Elise Nelson ◽  
Brian Keegan
Keyword(s):  
Combination Therapy ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Biologic Therapy ◽  
Topical Therapy ◽  
Additional Treatment ◽  
Physician Global Assessment ◽  
Life Questionnaire ◽  
Open Label

Biologic therapy has been an important addition to the armamentarium of psoriasis drugs as they offer high efficacy with a better side effect profile than systemic agents. However, there are cases in which patients do not respond rapidly or lose their initial response to biologic therapy, thus requiring additional treatment. While biologic therapy could be switched from one agent to another, in many cases, patients have had no adverse events (AEs) and the remaining lesions are minimal. In such cases, the addition of a topical agent may be the best choice. This single-center, open-label observational study enrolled 20 patients ≥18 years of age with plaque psoriasis with ≤5% body surface area (BSA) involvement. Patients received biologic therapy for at least 24 weeks prior to baseline. Topical combination therapy with desoximetasone spray 0.25% was added twice daily for 4 weeks and then decreased to twice-daily application on 2 consecutive days per week to week 16. Topical therapy was effective and well tolerated. Body surface area decreased −1.20 by week 4. Physician global assessment (PGA) score improved by −1.10 at week 4 and by −1.50 at week 16. The mean BSA × PGA score was 8.85 at baseline and had declined by −4.90 by week 4, an effect that was maintained to week 16. The combination therapy was well tolerated and safe. There were no AEs considered related to study medications and no steroid-related AEs such as atrophy, striae, telangiectasia, or folliculitis. Patients showed improvements in dermatology quality of life questionnaire scores. A treatment satisfaction questionnaire showed that overall patients were satisfied with the treatment regimen and found it to be convenient at all time points.

Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study

Rheumatology ◽  
2021 ◽  
Author(s):  
Alexis Ogdie ◽  
Daniel B Shin ◽  
Thorvardur Jon Love ◽  
Joel M Gelfand
Keyword(s):  
Cohort Study ◽  
Psoriatic Arthritis ◽  
Surface Area ◽  
Body Surface Area ◽  
General Practitioners ◽  
Body Surface ◽  
Strong Predictor ◽  
Population Based ◽  
Health Improvement ◽  
Psoriasis Severity

Abstract Objective Increasing psoriasis severity has been associated with comorbidities including cardiovascular disease. The objective of this study was to examine the association of psoriasis severity with the development of psoriatic arthritis (PsA). Methods A prospective population-based cohort study was performed within The Health Improvement Network, a United Kingdom medical record database. Patients aged 25–60 years with a code for psoriasis were randomly selected between 2008–2011. Questionnaires were sent to their general practitioners to confirm the diagnosis of psoriasis and provide the patient’s approximate body surface area (BSA). Incidence of PsA was calculated by BSA, and Cox proportional hazard ratios were used to examine the risk of developing PsA by BSA category after adjusting for other covariates. Results Among 10 474 questionnaires sent, 9,987 (95%) were returned, 9,069 (91%) had confirmed psoriasis, and BSA was provided for 8,881 patients: 52% had mild psoriasis, 36% moderate psoriasis, and 12% severe psoriasis. The mean age was 46, and 49% were female. Mean follow-up time was 4.2 years (SD 2.1); the incidence of PsA was 5.4 cases per 1,000 person years. After adjusting for age and sex, BSA >10% (HR 2.01, 95% CI: 1.29–3.13), BSA 3–10% (HR 1.44, 95% CI: 1.02–2.03), obesity (HR 1.64, 95% CI: 1.19–2.26), and depression (HR 1.68, 95% CI: 1.21–2.33) were associated with incident PsA. Conclusions In this large prospective cohort study, BSA assessed by general practitioners was a strong predictor of developing PsA, and obesity and depression were additive risk factors.

Sign in / Sign up

Export Citation Format

Share Document